Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Merrill

Showing results (271-280 of 414) with videos related to

Pageof 42
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|March 19, 2016
Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy OutcomesCecile M Yelnik, T Flint Porter, D Ware Branch, et al.
Annals of the Rheumatic Diseases|August 28, 2007
Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosusA H Sawalha, K M Kaufman, J A Kelly, et al.
The New England Journal of Medicine|March 16, 2022
Phase 2 Trial of Iberdomide in Systemic Lupus ErythematosusJoan T Merrill, Victoria P Werth, Richard Furie, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2024
Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled TrialJoan T Merrill, Yoshiya Tanaka, David D'Cruz, et al.
Annals of the Rheumatic Diseases|January 27, 2018
Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodiesMimi Y Kim, Marta M Guerra, Elianna Kaplowitz, et al.
Arthritis and Rheumatism|August 29, 2009
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosusDaniel J Wallace, William Stohl, Richard A Furie, et al.
Lupus Science & Medicine|April 15, 2017
Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupusTeresa Aberle, Rebecka L Bourn, Hua Chen, et al.
Chemical Reviews|May 12, 2021
Quantum Chemistry Calculations for MetabolomicsRicardo M Borges, Sean M Colby, Susanta Das, et al.
Arthritis and Rheumatism|December 1, 2011
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusRichard Furie, Michelle Petri, Omid Zamani, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 17, 2023
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 TrialJoan T Merrill, Joel Guthridge, Miles Smith, et al.
Pageof 42

Showing results (271-280 of 414) with videos related to

Sort By:
Pageof 42
Arthritis & Rheumatology (Hoboken, N.J.)|March 19, 2016
Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy OutcomesCecile M Yelnik, T Flint Porter, D Ware Branch, et al.
Annals of the Rheumatic Diseases|August 28, 2007
Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosusA H Sawalha, K M Kaufman, J A Kelly, et al.
The New England Journal of Medicine|March 16, 2022
Phase 2 Trial of Iberdomide in Systemic Lupus ErythematosusJoan T Merrill, Victoria P Werth, Richard Furie, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2024
Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled TrialJoan T Merrill, Yoshiya Tanaka, David D'Cruz, et al.
Annals of the Rheumatic Diseases|January 27, 2018
Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodiesMimi Y Kim, Marta M Guerra, Elianna Kaplowitz, et al.
Arthritis and Rheumatism|August 29, 2009
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosusDaniel J Wallace, William Stohl, Richard A Furie, et al.
Lupus Science & Medicine|April 15, 2017
Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupusTeresa Aberle, Rebecka L Bourn, Hua Chen, et al.
Chemical Reviews|May 12, 2021
Quantum Chemistry Calculations for MetabolomicsRicardo M Borges, Sean M Colby, Susanta Das, et al.
Arthritis and Rheumatism|December 1, 2011
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusRichard Furie, Michelle Petri, Omid Zamani, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 17, 2023
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 TrialJoan T Merrill, Joel Guthridge, Miles Smith, et al.
Pageof 42